The global endocrinology drugs market is expected to grow at a CAGR of 6.69% during the period 2016-2020.
As vendors are facing the problem of a decline in venture capital investment, they are increasingly following the strategy of outsourcing. Different parts of research such as product characterization testing and toxicology testing are outsourced to third-party research organizations.
Similarly, some vendors outsource the pharmaceutical product manufacturing or the entire manufacturing process to contract manufacturing organizations. This reduces the operational costs, as most companies do not have to maintain expensive R&D laboratories and scientists. Pharmaceutical companies rely on the contract manufacturing organizations based in India, China, Russia, and Eastern Europe to manufacture and process their products.
The prevalence of diabetes is rising because of obesity, unhealthy diet, and lack of physical activity among individuals. The prevalence of hypogonadism also increases in men with diabetes, human immunodeficiency virus (HIV), chronic obstructive pulmonary disease, heart or renal disease, or in individuals who are on opiate or glucocorticoid therapy. Thus, the increase in the prevalence of these diseases will lead to the increase in the intake of medications, propelling the market growth.
Further, the report states that the patent expiry of major approved drugs is expected to impact the market adversely and slow down its growth during the forecast period.
- AbbVie Inc.
- AstraZeneca PLC
- Eli Lilly and Co.
- Merck & Co
- Novo Nordisk AS
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Key buying criteria
PART 06: Pipeline portfolio
PART 07: Market landscape
PART 08: Market segmentation by application
PART 09: Global diabetes drugs market
PART 10: Global testosterone replacement therapy market
PART 11: Global human growth hormone market
PART 12: Global thyroid hormone disorder drugs market
PART 13: Geographical segmentation
PART 14: Market drivers
PART 15: Impact of drivers
PART 16: Market challenges
PART 17: Impact of drivers and challenges
PART 18: Market trends
PART 19: Vendor landscape
For more information visit http://www.researchandmarkets.com/research/p3wtq4/global